atenolol has been researched along with simvastatin in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.03) | 18.2507 |
| 2000's | 12 (36.36) | 29.6817 |
| 2010's | 18 (54.55) | 24.3611 |
| 2020's | 2 (6.06) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, L; He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Wang, Y; Zhang, W | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bloomer, WD; Papadopoulou, MV; Rosenzweig, HS | 1 |
| Lee, TH | 1 |
| Khadipash, LA; Kiseleva, NV; Kosmatova, OV; Mamedov, MN; Oganov, RG; Perova, NV | 1 |
| Ito, MK; Pieper, JA; Talbert, RL | 1 |
| Diener, HC | 1 |
| Kumar, V; Shah, RP; Singh, S | 1 |
| Ang, PS; Su, DH; Tow, SL | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Afzal, R; Pais, P; Pogue, J; Sigamani, A; Xavier, D; Yusuf, S | 1 |
| Afzal, R; Eikelboom, J; Gupta, R; Mohan, V; Pais, P; Sigamani, A; Teo, K; Thomas, N; Xavier, D; Yusuf, S | 1 |
| Chakraborty, BS; Desai, J; Ghosh, C; Jha, V; Khamar, B; Patel, A; Shah, G; Shah, T | 1 |
| Bai, YM; Chou, YH; Liang, CS; Liou, YJ | 1 |
| Carey, KM; Comee, MR; Donovan, JL; Kanaan, AO | 1 |
| Afzal, R; Gao, P; Pais, P; Sigamani, A; Teo, KK; Xavier, D; Yusuf, S | 1 |
| Gugssa, SA; Johnston, JC | 1 |
| Bautista, LE; Casas, JP; Chirinos, JA; Ferrante, D; Ferreccio, C; Herrera, VM; Medina-Lezama, J; Miranda, JJ; Oróstegui Arenas, M; Pérez, CM; Pichardo, R; Sánchez Abanto, JR; Schapochnik, N; Silva, E; Vera-Cala, LM | 1 |
| Billot, L; Bompoint, S; Bots, ML; Cidambi, R; Field, J; Grobbee, DE; Patel, A; Poulter, N; Prabhakaran, D; Reddy, KS; Rodgers, A; Stanton, A; Thom, S | 1 |
| Billot, L; Bompoint, S; Brown, A; Burch, C; Burke, H; Cass, A; Hayman, N; Hillis, GS; Jan, S; Molanus, B; Neal, B; Patel, A; Peiris, D; Rafter, N; Reid, CM; Rodgers, A; Shiel, L; Togni, S; Tonkin, A; Usherwood, T; Webster, R | 1 |
| Arroll, B; Bramley, D; Bryant, L; Bullen, C; Crengle, S; Doughty, RN; Elley, CR; Harwood, M; Jackson, R; Milne, RJ; Parag, V; Rafter, N; Rodgers, A; Selak, V; Wadham, A | 1 |
| Bots, ML; Grobbee, DE; Lafeber, M; Patel, A; Prabhakaran, D; Rodgers, A; Spiering, W; Stanton, A; Thom, S; Visseren, FL; Webster, R | 1 |
| Cheruvu, HS; Devalapalli, MMR; Sampathi, S; Shivakumar, S; Veeravalli, VB; Yertha, T | 1 |
| Bosch, J; Dans, AL; Gamra, H; Gao, P; Joseph, P; Lopez, PC; Lopez-Jaramillo, P; Pais, P; Santoso, A; Talukder, S; Teo, K; Tyrwhitt, J; Xavier, D; Yeates, K; Yusoff, K; Yusuf, S | 1 |
| Abdulwahab, S; Eissa, MS; Elsonbaty, A; Hassan, WS; Serag, A | 1 |
| Bosch, J; Christou, C; Dagenais, G; Dans, A; Gamra, H; Gao, P; Girish, P; Joseph, P; López-Jaramillo, P; McCready, T; Pais, P; Rocha, C; Santoso, A; Talukder, S; Teo, K; Tyrwhitt, J; Xavier, D; Xavier, F; Yeates, K; Yusoff, K; Yusuf, S | 1 |
3 review(s) available for atenolol and simvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.
Topics: Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Drug Combinations; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Simvastatin; Stroke | 2012 |
Syphilitic aortic aneurysm with spastic paraparesis: a novel presentation and review of the literature.
Topics: Aorta, Thoracic; Aortic Aneurysm, Thoracic; Atenolol; Disease Outbreaks; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Paraparesis, Spastic; Penicillins; Simvastatin; Spinal Cord Compression; Syphilis; Time Factors | 2012 |
10 trial(s) available for atenolol and simvastatin
| Article | Year |
|---|---|
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atenolol; Capsules; Cardiovascular Agents; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Drug Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Platelet Aggregation Inhibitors; Primary Prevention; Ramipril; Research Design; Secondary Prevention; Simvastatin; Treatment Outcome | 2009 |
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Risk Reduction Behavior; Simvastatin; Treatment Outcome | 2009 |
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Antihypertensive Agents; Area Under Curve; Aspirin; Atenolol; Biological Availability; Capsules; Cardiovascular Diseases; Chromatography, Liquid; Cross-Over Studies; Drug Combinations; Drug Interactions; Humans; Hydrochlorothiazide; Hypolipidemic Agents; Male; Middle Aged; Platelet Aggregation Inhibitors; Ramipril; Risk Factors; Simvastatin; Tandem Mass Spectrometry; Young Adult | 2010 |
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.
Topics: Administration, Oral; Aged; Analysis of Variance; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Capsules; Cardiovascular Diseases; Cholesterol, LDL; Creatinine; Dietary Supplements; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Heart Rate; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; India; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Potassium; Ramipril; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2012 |
Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Female; Humans; Hydrochlorothiazide; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin; Treatment Outcome | 2013 |
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Australia; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cholesterol; Drug Combinations; Drugs, Generic; Female; General Practice; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lisinopril; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Primary Prevention; Prospective Studies; Risk Factors; Simvastatin; Sodium Chloride Symporter Inhibitors; Tablets; Time Factors; Treatment Outcome | 2015 |
Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lisinopril; Male; Medication Adherence; Middle Aged; New Zealand; Primary Health Care; Regression Analysis; Risk Factors; Simvastatin; Young Adult | 2014 |
Impact of switching from different treatment regimens to a fixed-dose combination pill (polypill) in patients with cardiovascular disease or similarly high risk.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Aspirin; Atenolol; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Drug Substitution; Europe; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; India; Lisinopril; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2017 |
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.
Topics: Adrenergic beta-1 Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Diuretics; Double-Blind Method; Drug Combinations; Female; Global Health; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Primary Prevention; Ramipril; Retrospective Studies; Simvastatin | 2018 |
Polypill with or without Aspirin in Persons without Cardiovascular Disease.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Incidence; Male; Medication Adherence; Middle Aged; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin | 2021 |
20 other study(ies) available for atenolol and simvastatin
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Prediction of volume of distribution values in human using immobilized artificial membrane partitioning coefficients, the fraction of compound ionized and plasma protein binding data.
Topics: Blood Proteins; Chemistry, Physical; Computer Simulation; Humans; Membranes, Artificial; Models, Biological; Pharmaceutical Preparations; Protein Binding; Tissue Distribution | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
Topics: Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Humans; Imidazoles; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Structure-Activity Relationship; Triazoles | 2017 |
In the past 12 to 18 months, my level of anxiety has increased significantly. I have been on atenolol and simvastatin (Zocor) for the past couple of years. Is there anything in these drugs that could cause this anxiety?
Topics: Adrenergic beta-Antagonists; Anxiety; Atenolol; Humans; Simvastatin | 1998 |
[Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].
Topics: Adult; Antihypertensive Agents; Atenolol; Atorvastatin; Blood Pressure; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Indapamide; Male; Metabolic Syndrome; Middle Aged; Perindopril; Pyrroles; Simvastatin; Treatment Outcome | 2003 |
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Niacin; Obesity; Risk Factors; Simvastatin | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke | 2003 |
LC and LC-MS methods for the investigation of polypills for the treatment of cardiovascular diseases. Part 1. Separation of active components and classification of their interaction/degradation products.
Topics: Aspirin; Atenolol; Atorvastatin; Cardiovascular Agents; Chromatography, High Pressure Liquid; Drug Combinations; Drug Interactions; Drug Stability; Heptanoic Acids; Hydrochlorothiazide; Lisinopril; Pravastatin; Pyrroles; Simvastatin; Spectrometry, Mass, Electrospray Ionization | 2008 |
Bilateral posterior ischemic optic neuropathy associated with use of sildenafil.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Atenolol; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diltiazem; Dose-Response Relationship, Drug; Drug Interactions; Drugs, Chinese Herbal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypotension; Male; Optic Nerve; Optic Neuropathy, Ischemic; Phosphodiesterase Inhibitors; Piperazines; Purines; Retinal Artery; Risk Factors; Sildenafil Citrate; Simvastatin; Sulfones; Vision, Low | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Acute renal failure after paliperidone overdose: a case report.
Topics: Acidosis; Acute Kidney Injury; Adult; Anticholesteremic Agents; Antihypertensive Agents; Antipsychotic Agents; Atenolol; Blood Urea Nitrogen; Creatinine; Dose-Response Relationship, Drug; Drug Overdose; Drug Therapy, Combination; Humans; Isoxazoles; Male; Paliperidone Palmitate; Pyrimidines; Self Medication; Simvastatin | 2012 |
A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.
Topics: Aged; Antihypertensive Agents; Aspirin; Atenolol; Cardiovascular Diseases; Cohort Studies; Cost-Benefit Analysis; Developing Countries; Drug Combinations; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Latin America; Male; Markov Chains; Middle Aged; Quality-Adjusted Life Years; Ramipril; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Sodium Chloride Symporter Inhibitors | 2013 |
Hansen solubility parameters for assay method optimization of simvastatin, ramipril, atenolol, hydrochlorothiazide and aspirin in human plasma using liquid chromatography with tandem mass spectrometry.
Topics: Aspirin; Atenolol; Chromatography, Liquid; Humans; Hydrochlorothiazide; Ramipril; Reproducibility of Results; Simvastatin; Solubility; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2017 |
Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.
Topics: Algorithms; Aspirin; Atenolol; Capsules; Cardiovascular Diseases; Chromatography, High Pressure Liquid; Humans; Hydrochlorothiazide; Least-Squares Analysis; Ramipril; Simvastatin; Spectrophotometry, Ultraviolet | 2020 |